TrialPloS one2022

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial.

Robert S Wallis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.